Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

GlaxoSmithKline PLC (NYSE:GSK)

41.56
Delayed Data
As of Feb 24
 +0.07 / +0.17%
Today’s Change
37.20
Today|||52-Week Range
45.58
+7.92%
Year-to-Date
GSK Regular Dividend: GSK began trading ex-dividend on 02/22/17. A $0.5758 dividend will be paid to shareholders of record as of 02/24/17.
Better Buy: Eli Lilly and Co vs. GlaxoSmithKline plc
Feb 25 / MotleyFool.com - Paid Partner Content
Top Ranked Growth Stocks to Buy for February 23rd
Feb 23 / Zacks.com - Paid Partner Content
Intercept (ICPT) Q4 Loss Wider than Expected, Revenues Beat
Feb 24 / Zacks.com - Paid Partner Content
Pfizer's Leukemia Candidate Gets Priority Review in U.S.
Feb 22 / Zacks.com - Paid Partner Content
Radius Health (RDUS) Posts Wider Loss in Q4
Feb 24 / Zacks.com - Paid Partner Content
Gilead Sciences Raises Dividend by Double Digits
Feb 22 / GuruFocus News - Paid Partner Content
Pharma Stock Roundup: Is BMY the Next Acquisition Target? Priority Review for PFE, No...
Feb 24 / Zacks.com - Paid Partner Content
Troubling Trial Data Weighed on Agenus Inc Stock Today
Feb 22 / MotleyFool.com - Paid Partner Content
Bayer (BAYRY) Misses on Q4 Earnings; Revenues in Line
Feb 23 / Zacks.com - Paid Partner Content
3 Things Gilead Sciences' CEO Just Said That You'll Want to Know
Feb 22 / MotleyFool.com - Paid Partner Content

Today’s Trading

Previous close41.49
Today’s open41.25
Day’s range41.18 - 41.56
Volume3,197,341
Average volume (3 months)3,957,010
Market cap$102.0B
Dividend yield4.83%
Data as of 4:02pm ET, 02/24/2017

Growth & Valuation

Earnings growth (last year)-90.48%
Earnings growth (this year)+10.00%
Earnings growth (next 5 years)+11.22%
Revenue growth (last year)+2.85%
P/E ratio371.1
Price/Sales2.52
Price/Book72.83

Competitors

 Today’s
change
Today’s
% change
ABBVAbbVie+0.15+0.24%
BMYBristol-Myers Squibb+0.67+1.20%
SNYSanofi+0.19+0.45%
AGNAllergan-1.66-0.67%
Data as of 4:02pm ET, 02/24/2017

Financials

Next reporting dateApril 26, 2017
EPS forecast (this quarter)$0.65
Annual revenue (last year)$37.5B
Annual profit (last year)$1.2B
Net profit margin3.27%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Major
Chief Executive Officer &
Executive Director
Andrew Philip Witty
Chief Financial Officer &
Executive Director
Simon Dingemans
Corporate headquarters
Brentford, Greater London

Forecasts


Search for Jobs